Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (September 2015)
22 slides from Can-fite Biopharma's investor presentation, Sep 9, 2015
Slide 1: Can-Fite Presentation — September 2015
‘ CANFITE BioPharma Ltd. Can-Fite Presentation — September 2015 ‘Small Molecules For Big Clinical Needs™ (NYSE MKT:CANF) (TASE:CFB!)
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time
Slide 3: Advanced clinical stage drug development company
| * Advanced clinical stage drug development company * Phase Il and Phase Ii/iII clinical studies * Small molecule drugs * Autoimmune Inflammatory diseases * Cancer * Sexual Dysfunction * Company Operations * Headquarters and Discovery Labs ~ Petach-Tikva, Israel * Drug Development & Clinical Operat
Slide 4: Why Cancer Does Not Metastasize to Muscle?
; F Concept to Technolog Why Cancer Does Not Metastasize to Muscle? 2 <S ———— ss Ss exc pee Apoptosis ecient) “aM A, Adenosine Receptor (AAR) (NYSE MKT:CANF) (TASE:CFBI) CANFITE a BioPharma Ltd.
Slide 5: Platform Technology
Platform Technolo * Therapeutic Target * Az adenosine receptor (A3AR) * Highly expressed in inflammatory and cancer cells * Drug product * Small molecules * Orally bioavailable drugs * Therapeutic Effect * Anti-inflammatory and anti-cancer effects in Phase II studies; Excellent safety profile * ABAR
Slide 6: Drug Development Pipeline
Drug Development Pipeline Indication/Drug Pre-clinical Phase! Phase ll Phase Il Psoriasis — CF101 In preparation Rheumatoid Arthritis — CF101 In preparation Liver Cancer — CF102 Ongoing CF602 On-going Glaucoma — CF101 On-going Operated by our subsidiary Ophthalix (OTCQB: OPLI) (NYSE MKT:CANF) (TASE:
Slide 7: Corporate Partnerships: Regional out-licensing deals
ersh e Pa Corpo Regional out-licensing deals - “$10 million received to date KWANG DONG Poamincetris GO [Traded on South Korean Stock Exchange (Ticker: A009290)], * Exclusive regional license to develop and commercialize CF101 for the treatment of rheumatoid arthritis in Korea * Up to $1.5 M in upfr
Slide 8: CF101 — Anti-Inflammatory Effect
CF101 — Anti-Inflammatory Effect Properties Anti-Inflammatory Effect . © Highly Selective AsAR Agonist Proof of concept in pre-clinical * Nucleoside derivative pharmacology studies: Rheumatoid Arthritis Osteoarthritis Inflammatory Bowel Disease Uveitis © Molecular weight - 510.29 © Water insoluble *
Slide 9: Rheumatoid Arthritis - Positive Data from Phase II Study
: Rheumatoid Arthritis - Positive Data from Phase II Study Phase IIb study, Placebo controlled; 79 patients; enrolled based on the A3 Adenosine receptor biomarker x * All Patients Patients with No Prior SystemicTherapy 80% 80% @ cF101 (n=8) 1B Placebo (n=8) g 8 & 60% o 4 8 @ 2 60% 8 p=0.035 ‘Treatme
Slide 10: CF101 - Psoriasis Phase II/III Study Protocol
CF101 - Psoriasis Phase Il/Ill - Study Protocol * Double-blind, placebo-controlled study to test efficacy of CF101 in 320 patients with moderate-to-severe plaque psoriasis * 3.arms: 1 mg, 2 mg and of CF101 and placebo * allpatients receiving placebo were switched to either 1. mg or 2 mg CF101 after
Slide 11: Psoriasis — Data from Phase II/III Study
Psoriasis — Data from Phase II/III S y The study did not achieve the primary endpoint of PASI 75 at 12 weeks; Excellent safety profile in all tested dosages; Positive linear dataon Weeks 12 to 32 Significant Linear Effect of CF101 on PASI Scores through 32 Weeks of Treatment E PASI (2% of patients)
Slide 12: PASI Response in Treatment-Naive Patients
PASI 90 Response in Treatment-Naive Patie! Statistically Significant Linear PASI 90 Response 30% a , -HENo prior systemic therapy 26.9% -®-Prior systemic therapy 25% g PASI 90 (% of patients) g 10% 5% 0% 16 20 24 28 32 Treatment Week (Open Label Period) *MTX, Biological Drugs CANFITE BioPharma Lid.
Slide 13: Psoriasis — Positive Linear Data on Weeks 16 to 32
Psoriasis — Positive Linear Data on Weeks 12 to 32 > PASI 75 - 35.3% by 32 weeks of treatment; linear response > PASI mean percent improvement- 57% (p<0.001); linear from 16 to 32 weeks. > PASI 90 and PASI 100 - 24.7% and 10.6%, respectively by 32 weeks of treatment; linear increase. > Historical pl
Slide 14: CF101 Compares Favorably To Celgene's Otezla
CF101 Compares Favorably To Celgene’s Otezla Otezla® F101 ~ Otezla (apremilast) Phase III Data Pood Statistically significant cumulative and linear nica jibaicisabeed inate) improvement during weeks 16 to 32. Pacebo + Peotboligemiast —& Apveniast Patients Achieving PASETS Response CO) bree EHDA Stuy
Slide 15: CF101 vs Otezla and Placebo PASI Response
57.1% 24.7% 10.6% CF101, Can-Fite at week 32 at week 32 at week 32 no plateau at week 32 no plateau at week _no plateau at week 32 32 ~57% 11.4% Not analyzed at week 16 Otezla, Celgene at week 24 as there were too start to plateau at week 16.7% few participants 20 at week 24 at week 16 Placebo Fane
Slide 16: Phase II/III Safety Comparable to Placebo
Phase II/III Safety Comparable to Placeb: PT crcizneso | raion | Vital Signs No significant change No significant change ECG No significant change No significant change Clinical Laboratory No significant change No significant change Any Adverse Event (AE) 25.5% 19.6% Infection AE 6.9% 8.8% “Related”
Slide 17: CF102 — Anti-Cancer Effect
CF102—-A\ Properties Anti-Cancer Effect * Highly Selective A3AR Agonist Proof of concept in pre-clinical pharmacology studies: © Hepatocellular Carcinoma * Colon Carcinoma © Water insoluble * Prostate Cancer * Orally bioavailable * Melanoma * Half life time in blood — 12 hours * Nucleoside derivativ
Slide 18: Liver Cancer — Phase II Global Study Ongoing
Liver Cancer — Phase II Global Study Ongoin Phase Il - Ongoing . Patient enrolment for a global Phase II study has been initiated and designed as follows: * Second-Line Treatment * Advanced Hepatocellular Carcinoma; Child-Pugh B Zany AN) + 78 patients; rt PRON cass P' aes * US, Europe and Israel + P
Slide 19: CF602 — Sexual Dysfunction Safe Drug
CF6! Sexual Dysfunctio Safe Dru. Chemical Structure Properties ¢ A3AR allosteric modulator seq © Molecular weight — 411.34 cy 7 ° Water insoluble a SC) © Orally bioavailable © Belong to the family of imidazoquinoline derivatives 1H-Imidazo[4,5-c]quinolin-4-amine Derivatives Current status * Manufact
Slide 20: CF602 — Improvement of Erectile Dysfunction
CF602 — Improvement of Erectile Dysfunctio Diabetic Rat Model Intra-cavernous pressure (ICP)/mean arterial pressure (MAP) ratios Control 24h mNCF 602 24h ME Control Sd (mC 602 5d 03. ” 3 oa a g Eos s 00. F602 CF602 acts as a vaso-relaxant to promote smooth muscle relaxation and penile erection Histo
Slide 21: Equity Profile
Equity Profile Ticker on NYSE: CANF Ticker on Israeli TASE: CFB! Price of ADR: $1.77 (1 ADR = 2 Ordinary Shares) 52 Week Range: $1.46 - $5.83 Shares Out: 21.3M Ordinary Shares Market Capitalization: ~S20M Avg. Trading Volume (30 day): 103,763 ADRs Cash as of June 30: $7,747,000 As of September 1, 20
Slide 22: Spotlight on 12 Month Milestones
Spotlight on 12 Month Milestones CF101 - Psoriasis (~$9B Opportunity) Reported Favorable Follow-Up Data from Phase II/III Study in Patients with Psoriasis Vv) Preparing Clinical Protocol For Phase III Study H2-2015 CF101 - Rheumatoid Arthritis (~$38B Opportunity) Reported Positive Data From Phase II
Can-Fite BioPharma — Investor Presentation (September 2015) on 6ix